CME Group Inc. · NASDAQ:CME
CME — Cbot Holdings — Merger or Acquisition (May 2007)
13 slides from CME's merger presentation, May 11, 2007
Slide 1: Filed by Chicago Mercantile Exchange Holdings Inc. pursuant to Rule 425
Filed by Chicago Mercantile Exchange Holdings Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934, as amended. Subject Company: CBOT Holdings, Inc. Subject Company’s Commission File No.: 001-32650
Slide 2: CME/CBOT Analyst Call
CME/CBOT Analyst Call May 11, 2007
Slide 3: Discussion of Forward-Looking Statements
Discussion of Forward-Looking Statements Forward-Looking Statements This presentation may contain forward-looking information regarding Chicago Mercantile Exchange Holdings Inc. and CBOT Holdings, Inc. and the combined company after the completion of the merger that are intended to be covered by the
Slide 4: Transaction Summary
Transaction Summary For each CBOT share, shareholders will receive Consideration: 0.3500 CME shares All stock transaction; cash election eliminated CME Shareholders: 65.4% Pro Forma Ownership: CBOT Shareholders: 34.6% Accretive to earnings of the combined company on a Expected Accretion: cash basis
Slide 5: Best Strategic Alternative - Most Long Term Value
Best Strategic Alternative - Most Long Term Value • Greater immediate and long term growth opportunities OTC opportunities are larger with CME Greater diversity of revenue Complementary products increase revenue/growth synergies CME and CBOT are operationally superior and can grow from Day 1 Both co
Slide 6: Platform for Diversified Growth
Platform for Diversified Growth CBOT/CME have much greater presence across all major asset classes Q1 2007 Combined ADV by Product Line (in 000’s) 8,000 CBOT/CME 8,000 8,000 CBOT/ICE 6,671 6,000 6,000 6,000 CME ICE CBOT CBOT 4,000 4,000 4,000 3,032 2,305 2,000 2,000 2,000 724 818 555 586 531 154 142
Slide 7: Pro Forma ADV – Q107
Pro Forma ADV – Q107 contracts in 000s Pro Forma Q107 ADV 12,000 10,320 10,068 10,000 2,773 3,866 8,000 6,000 4,607 7,295 4,000 3,431 6,454 3,866 2,000 1,512 741 0 CBOT/CME Eurex/ISE CBOT/ICE Euronext.liffe NYMEX Note: [1] Eurex and Euronext.liffe include individual equity and equity index options [
Slide 8: Basis for Revised Proposal
Basis for Revised Proposal Several months of integration planning have yielded Expected cost synergies of at least $150M Potential revenue and growth synergies of at least $75M Continued efficiencies from clearing services Speed to integration – accelerated original trading floor and Globex consolid
Slide 9: Larger and More Certain Revenue Synergies
Larger and More Certain Revenue Synergies Largest/Most Scalable Platforms • Trade matching • Clearing processing Greater Product Innovation Broadest Global Presence • Yield curve products • Immediate customer base • Spread products/functionalities $75M+ growth in 80+ countries • Strong entry point f
Slide 10: Larger, More Valuable OTC Growth Opportunities
Larger, More Valuable OTC Growth Opportunities CBOT/CME is better positioned to immediately pursue the full scope of OTC growth opportunities CBOT/CME will have: $300,000 $262,296 • Largest global exchange-traded derivatives market • Largest global derivatives clearing house $250,000 • Largest globa
Slide 11: Positioned for Global Growth
Positioned for Global Growth CBOT/CME will pursue relatively untapped global growth strengthened by: A broad product offering that has wide global appeal Expansive distribution with international hubs and global customers CBOT/CME customers in more than 80 countries 7 European/Asian hubs © Chicago M
Slide 12: Fixed Price Tender Offer of $560 per CME share
Fixed Price Tender Offer of $560 per CME share Details The company has committed to commence a cash tender offer up to $3.5 billion in common stock of the combined company, or approximately 12% of the combined company’s outstanding shares Fixed price tender at $560 per share, contingent upon deal cl
Slide 13: Summary - Transaction Milestones
Summary - Transaction Milestones CBOT/CME have made tremendous progress since October Transaction Milestones Operational Milestones • Definitive merger • Identified at least agreement $150M in expected cost synergies • Joint proxy/registration statement declared • Post-merger effective management te